Updates

  1. 137 new fund letters and reports, each with its own page: Kayne Anderson Rudnick (48 market briefings, KayneCast episodes and TV commentaries), Shelton Capital Management (48 shareholder reports and a commentary), Lakehouse Capital (10 Small Companies Fund letters), Smead (5 newsletters), RIT Capital Partners (5 monthly commentaries), Kovitz, Legal & General, Generation, Hosking, Marram, Munro, Oldfield and others.
  2. 200 new fund letters and reports, each with its own page: Spheria (41 monthly reports), Peapack Private (41 weekly recaps and planning newsletters), Fort Washington (23), Polen Capital (15), Aristotle Pacific (14), Riverwater (13), Chou (10), Apollo Asia Fund (8, back to 1998), Personal Asset Trust, Rockwood Strategic, J Capital Research, I/O Fund, Penn Davis McFarland, Pomona and others.
  3. Investor pages have one Investments tab with shares, changes, % owned, class, market cap and Market cap and Status filters, a Funds tab listing each fund the firm runs, and assets under management from Form ADV. The Investors table shows AUM and current investments, and its search finds investors by what they hold.
  4. Filters, search and sort stay as you left them when you come back to a section. Person cards look like book cards. Company pages name their Investors tab Ownership. Kind and Sector filters use four kinds and GICS sectors with industries. Dead links left the Links tabs.
  5. 190 more investors from fiscal.ai's list, with their sites, letters, partners and 13F holdings; 556 more partner descriptions. Experts now lists only people.
  6. Fund letters lists 144 new documents from 23 firms, each with its own page: a summary, key insights and quotes. Among them: 37 BlackRock articles, 21 Value Partners monthly notes, eight Baron Capital letters, six Stone Sentinel letters to partners, seven Value Line portfolio manager Q&As, BNY's 2026 earnings releases and Starboard Value's 2026 conference presentations.
  7. 584 more investors, with their websites, 6,776 letters from their own sites, 1,385 partners with pages and the 13F holdings of 213 firms. New letters arrive daily from 290 more archives.
  8. Media and Companies filter by GICS sector and industry group, taken from the companies an episode or page names. 1,860 more company pages show a logo, the SEC's list included.
  9. The home page counts what the platform holds and lists features such as the document reader, the player and saved marks. Settings sits at the foot of the rail. Book cards are a quarter wider, so rows hold fewer. Companies drops the Named in filter, and the Role list in your account runs A to Z.
  10. Investor pages of 13 firms show their newsroom's latest posts. New 13F filings are read as the SEC publishes them.
  11. Investor pages have an Investments tab: 13,975 holdings for 105 investors, from their 13F filings with the SEC and their own portfolio pages, with status and sector. 7,338 more companies have a page of their own.
  12. A podcast or YouTube episode keeps playing while you move around the site, in a bar with skip, speed and volume. Media tables show each episode's length and description.
  13. Press releases come from each company's own newsroom (167 companies); SEC filings sit on the Filings tab. Tickers name their exchange, and a company's Experts tab includes guests whose episode description names it.
  14. Letter types now include Market commentary, Fact sheet, Interim report, Annual report, Proxy circular and Governance document. The reader opens over the whole window.
  15. Partners of investment firms have 2,836 appearances and 580 pieces of writing on their pages; Derek Sivers's page lists every book he rates, with his rating.
  16. Fund letters lists three Akre Focus shareholder reports: the ETF's annual report for the year to July 2026, its semi-annual report to January 2026 and the fund's semi-annual report to January 2025, each with its own page: a summary, key insights and quotes.
  17. 837 partners of 73 investment firms now have their own pages, with title, description, photograph and social accounts; Andreessen Horowitz partners' pages also list their writing on a16z.com.
  18. Company pages have a Press releases tab: 8,229 releases for 203 companies, from SEC filings and company newsrooms. Companies filter by For-profit or Non-profit. Own media is a table with filters. Media filters by sector and industry. Publication pages link their publisher in the description.
  19. The Unilever page's Letters tab shows what each fund letter says about Unilever, word for word with its page, and whether the letter is bullish, bearish, mixed or neutral. Filter by sentiment, and see 10 letters at a time.
  20. 492 more fund letters and 3,183 more articles show the day they were published, read from each letter's first page or each article's own page.
  21. The PDF reader has a search box: type words to see every match in the document and step through them. About 540 letters that were web pages, among them Oakmark's commentaries, Bill Miller's letters and Howard Marks's memos, now open in the reader.
  22. Person pages: recommendations open with tier 1 books; one button per organisation; transcripts sit on their episodes; the books on 129 reading lists joined the Recommends tabs.
  23. Companies lists every company with a ticker on the SEC's list, with a Source filter. A quote on a company page opens the letter at that page with the words marked. A company's Media tab lists only episodes that name it, and a new Own media tab lists its podcasts, publications and YouTube channel. Show pages link their publisher. A page opened from a table no longer shows that table's filters beside it.
  24. Company, investor and person pages show more of their social accounts: Facebook, TikTok, Bluesky, Medium, GitHub, Discord and podcast shows. Investor pages list every partner the firm's own team page names: 965 people across 73 investors, 98 for Andreessen Horowitz.
  25. About 170 more letters and papers open in the reader: Mohnish Pabrai's letters and transcripts from his site's new folder, and free copies of papers by Asness, Harvey, Altman, Lo and others from their own or their schools' sites.
  26. Every company a fund letter names has a page, with the letters and quotes that name it: 47 new pages, among them Atom Computing, Hugging Face, Rolls-Royce Holdings and Westinghouse Electric. Company pages have a Quotes tab.
  27. A person's Writing tab has a Type column and filter (Article, Essay, Transcript, Speech, Foreword, Interview and the rest), and Publication names only the publication that published each piece.
  28. Fund letters opens on the newest published letter, and a letter or paper found by search opens its own page here instead of the publisher's site.
  29. A letter or paper with a copy on the site opens its PDF over its page, with a button to open it in a new tab. Select text to highlight or underline it; signed-in readers keep their marks in their account. Each quote opens the PDF at its page with its words marked, and a Source link leads to the publisher's original.
  30. Fund letters lists 61 more documents, each with its own page: Fairfax's 2025 and 2026 interim reports, proxy circulars and 2025 annual report (with their French editions), 26 Charlie Munger meeting transcripts, talks and essays, Third Point's 2026 monthly reports and Malibu Life's interim results, and a Seth Klarman interview. Papers adds Richard Thaler's two 2020 editorials on nudges.
  31. Fund letters lists Lux Capital's letters for Q2 and Q3 2026, by Josh Wolfe, each with its own page: a summary, key insights and quotes.
  32. Fund letters lists Brookfield's letter to shareholders for Q3 2026, by Bruce Flatt, with its own page: a summary, key insights and quotes.
  33. Fund letters lists Howard Marks's memo of 11 November 2026, A Layman Thinks About AI, with its own page: a summary, key insights and quotes.
  34. Fund letters lists 118 more letters, each with its own page: 44 weekly commentaries by Jeremy Siegel from 2026, 31 issues of Van Tharp's newsletter from 2018, 23 Pabrai Investment Funds letters from 2021 to Q3 2026, 13 Efficient Frontier essays by William Bernstein, Oakmark's three 3Q 2026 commentaries, two Lindsell Train reports, a John Hussman comment and Third Point's Q3 2026 letter.
  35. 2,027 more books carry a one-line description in the Books table and on their pages; 7,067 of 7,715 have one, every tier 1, 2 and 3 book among them.
  36. Fund letters lists 187 more letters from 19 firms, among them Permanent Equity, Social Capital, Lux Capital, Square Peg, Bestinver, Cobas, Sequoia Fund, Marketfield and EquityCompass; each shows on its investor's page and has a page of its own.
  37. 2,928 more books carry a one-line description in the Books table and on their pages, so every tier 1, 2 and 3 book has one; 5,040 in all.
  38. Every publication on Newsletters has its own page: its writing, its writers, its staff and who recommends it. Investor pages have a Management tab; a company's Experts tab now leaves out its own people, who list under Management. Tabs on a phone move sideways only.
  39. Every fund letter and research paper has its own page: the thesis, the PDF, the companies and books it names, and for 176 letters and 24 papers so far a summary, key insights and quotes with their page.
  40. 99 books that no page listed now sit under their topics in Books, among them Caste, American Prometheus and Pale Blue Dot.
  41. Newsletters lists every newspaper, magazine, investment newsletter, journal and blog the reference holds, 442 in all, with the people who write there. The search box keeps your last 20 searches. You can create an account.
  42. 283 books that fund managers recommend in their letters are on the shelf, each with the letter's own words and page; investor pages have a Recommends tab.
  43. Person, company, investor and show pages link their own accounts on X, Threads, Instagram, LinkedIn, YouTube and Substack: 275 people, 552 companies and organisations, 88 investors and 478 shows.
  44. 716 more book recommendations name their source: the person's own reading list, letter, blog post, speech or interview, or an article that reports it. 232 of them quote the person's own words about the book, on the book card and on the book's page.
  45. Every US-listed company has a page with its SEC filings. Company pages list their experts and their management, past and present. Fund managers sit under Investors. Each show has a page of its episodes, and an episode page names its guests and hosts. Biographies lists groups, then people. Breadcrumbs show where a page sits.
  46. Media lists every podcast episode, video, interview and talk, over 10,000, by person, company, publisher and event; each filter searches its own choices. Books opens on its table, then Browse, then Authors and Recommenders. A filter's count no longer covers its arrow.
  47. A book that no company, country or subject page lists shows its topics under Where it sits in the reference. On a phone, a page's tabs scroll sideways only. Descriptions read the same on every page. See them in the Experts tab lists every expert the page names.
  48. Every podcast episode, video and interview has its own page with a video or audio player and a link to the source. Investor pages show each company's sector and market cap; firms such as Berkshire Hathaway have one page that holds their letters and their company tabs. Letters tabs filter by company and search the theses. Companies filter by Public, Private and Defunct and link each company's website.
  49. Every tab, view and search has its own address, such as /books/table/asset or /letters/companies, so Back works and a link opens the same place. Page addresses no longer end in .html. Fund letters, Investors, Companies and Papers load about a fifth of the data they did.
  50. Fund letters has a Companies tab: every company the letters name, with its market cap, sector, country, and how many letters and investors name it. Investor pages link each investor's website. Lists in table cells end with “… and N more” at every width.
  51. 1,120 more book summaries; descriptions for 373 papers; pages for 137 more companies, each with the fund letters that discuss it; 215 official photographs; search has its own page.
  52. 411 more books have a summary; person pages list 930 more of the books they wrote; 147 people show their official photograph.
  53. Every investor has a page with its letters and the companies they discuss; company pages list the investors whose letters name them.
  54. A Companies section at the top of the rail lists every company the books, experts and fund letters name.
  55. Person pages list letters, writing, profiles and links as sortable tables with filters, and show each person's companies as links; Fund letters show each letter's description in its own column.
  56. Experts show a checked job title and a short description of each person; 30 more people have photographs.
  57. Every company, fund, university and publication the experts work for has a page listing the people there.
  58. Fund letters show each letter's thesis and filter by it; 225 person pages list the essays, columns and newsletter issues the person wrote.
  59. Person pages list every essay and newsletter issue a person wrote, and their own books as a table in List view.
  60. Recommends shows the five largest kinds of book and the rest under More; browse pictures load sooner.
  61. Podcasts and talks link the original episode, filter by Audio and video or Press, and list each publisher once.
  62. Pages are wider, Recommends has List and Grid, and a filter clicked again turns off.
  63. Book cards sit in a ruled grid with Open Library and Goodreads links and each book's one-line note.
  64. Funds is now Investors; each investor's styles are buttons that filter the table.
  65. Podcasts and talks on a person's page filter by year and publisher and show as a list or a grid of pictures.
  66. Quotes show only people's own words: 472 summaries written by list sites are gone.
  67. Country pages open from Browse again, and every link on the shelf lands on a page.
  68. Subject and person pages show their sections as tabs, and each book appears once on a person's page.
  69. Book cards show the quote, who said it and the source; grids show five cards to a row.
  70. On a phone, a menu holds the sections, search, Updates, Feedback and dark mode.
  71. Feedback takes a screenshot of the page with no browser prompt, opens a screenshot full size when you click it, and clears itself once sent.
  72. Book cards are centred, search names the topic each book sits in, and any text cut short shows whole on hover.
  73. Search groups its results by kind: people, companies, geographies, subjects, topics, books, funds, fund letters and papers.
  74. The Books table lists who recommended each book by name, and the browser tab names the section you are in.
  75. Feedback can take a screenshot of the page, or one you paste or choose, and opens in the corner beside Updates.
  76. Each rail button reopens its section where you left it, and Browse, Table and People show on every book and subject page.
  77. Filters grey out choices that hold nothing instead of hiding them, and Books › People filters by authors or recommenders.
  78. Feedback takes a subject line and up to three screenshots.
  79. Biographies are grouped by the person they are about: 41 new pages, from Abraham Lincoln to Lee Kuan Yew.
  80. Sport splits into 23 sports, and Religion into one topic per faith.
  81. Book lists show as cards: the cover, one recommendation quote and every recommender by name.
  82. Seventeen subjects that had two or three pages under different names now have one page each.
  83. Every page lists its Experts as authors and recommenders, with a link to them on the Experts tab.
  84. Economics, Financial history, Financial panics and Accounting are subjects of their own, with one page per financial crisis.
  85. Book, person and subject pages open inside the app, so the tabs stay in view.
  86. 996 more book covers, and photographs or logos for 227 more people and companies.
  87. Books › Browse shows every subject as cards, and the rail holds Fund letters, Papers, Experts, Books and Funds.
  88. Every topic over 150 books splits into narrower topics, each with a page of its own.

Send feedback

What is it?
Screenshots, up to 3 (optional)
or paste one with Ctrl+V

We use your email only to reply to you.

Ikarian Capital

Asset Manager

AUM: $698M · Form ADV, 20 May 2026

i
ModernaNasdaq: MRNACurrentBiological Products, (No Diagnostic Substances)COM+175.0%$77M+$49M7.75%$80.7BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Kodiak Sciences Inc.Nasdaq: KODCurrentBiological Products, (No Diagnostic Substances)COM533,113-526,617-49.7%0.82%$65M+$15M6.51%$6.4BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
BRISTOL MYERS SQUIBB CONYSE: BMYCurrentPharmaceutical PreparationsCOM+2429.0%$62M+$59M6.23%$119BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Spdr Series TrustCurrentFundST STR SP BIOT-0.4%$47M-$0.2M4.76%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Vaxcyte, Inc.Nasdaq: PCVXCurrentBiological Products, (No Diagnostic Substances)COM400,465+11,783+3.0%0.25%$40M+$17M4.01%$9.2BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Disc Medicine, Inc.Nasdaq: IRONCurrentPharmaceutical PreparationsCOM+1882.1%$39M+$37M3.88%$3.5BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Abivax S.A.Nasdaq: ABVXCurrentPharmaceutical PreparationsSPONSORED ADS285,909-42,726-13.0%$38M-$84M3.86%$7.1BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Praxis Precision Medicines, Inc.Nasdaq: PRAXCurrentPharmaceutical PreparationsCOM NEW6,942-65,900-90.5%0.02%$31M-$0.3M3.13%$8.7BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
ACADIA PHARMACEUTICALS INCNasdaq: ACADCurrentPharmaceutical PreparationsCOM112,000+83,901+298.6%0.06%$26M+$26M2.66%$3.0BQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Celldex Therapeutics, Inc.Nasdaq: CLDXCurrentIn Vitro & In Vivo Diagnostic SubstancesCOM NEW518,500+40,000+8.4%0.66%$25M+$3M2.51%$2.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Newamsterdam Pharma CompanyCurrentORDINARY SHARES+43.5%$19M+$6M1.96%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Arcus Biosciences, Inc.NYSE: RCUSCurrentPharmaceutical PreparationsCOM734,559+230,000+45.6%0.51%$19M+$3M1.91%$2.3BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
INCYTE CORPNasdaq: INCYCurrentServices-Commercial Physical & Biological ResearchCOMNew$18M+$18M1.83%$23.6BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Amylyx Pharmaceuticals, Inc.Nasdaq: AMLXCurrentPharmaceutical PreparationsCOM561,459+443,959+377.8%0.44%$16M+$14M1.64%$3.4BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Rapport Therapeutics, Inc.Nasdaq: RAPPCurrentPharmaceutical PreparationsCOMNew$16M+$16M1.63%$1.4BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Pharvaris N.V.Nasdaq: PHVSCurrentPharmaceutical PreparationsCOM502,372+193,516+62.7%$16M+$5M1.60%$2.2BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Kymera Therapeutics, Inc.Nasdaq: KYMRCurrentBiological Products, (No Diagnostic Substances)COM+157.5%$15M+$9M1.50%$10.2BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Vera Therapeutics, Inc.Nasdaq: VERACurrentPharmaceutical PreparationsCL A400,000+90,000+29.0%0.55%$15M-$2M1.46%$1.9BQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Septerna, Inc.Nasdaq: SEPNCurrentPharmaceutical PreparationsCOM100,047+100,047New0.21%$13M+$13M1.27%$1.9BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Alto Neuroscience, Inc.NYSE: ANROCurrentPharmaceutical PreparationsCOM SHS482,338+75,000+18.4%1.20%$12M+$2M1.24%$1.1BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Cybin IncCurrentCOM NEW487,575+355,422+268.9%$12M+$11M1.22%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Contineum Therapeutics, Inc.Nasdaq: CTNMCurrentPharmaceutical PreparationsCL A594,666-213,208-26.4%$12M-$1M1.21%$355MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Cogent BiosciencesNasdaq: COGTCurrentPharmaceutical PreparationsCOM370,08400.0%0.21%$12M-$2M1.19%$4.8BQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Oric Pharmaceuticals, Inc.Nasdaq: ORICCurrentPharmaceutical PreparationsCOM522,765+522,765New0.50%$11M+$11M1.11%$800MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Summit Therapeutics Inc.Nasdaq: SMMTCurrentPharmaceutical PreparationsCOMNew$11M+$11M1.11%$8.5BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
ANI PHARMACEUTICALS INCNasdaq: ANIPCurrentPharmaceutical PreparationsCOM149,065-123,020-45.2%$11M-$12M1.09%$1.6BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Enliven Therapeutics, Inc.Nasdaq: ELVNCurrentPharmaceutical PreparationsCOM232,055+105,514+83.4%0.32%$11M+$4M1.07%$3.4BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Maze Therapeutics, Inc.Nasdaq: MAZECurrentBiological Products, (No Diagnostic Substances)COM301,402-77,597-20.5%0.55%$8M-$3M0.82%$1.8BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
C4 Therapeutics, Inc.Nasdaq: CCCCCurrentBiological Products, (No Diagnostic Substances)COM STK1,933,000-500,000-20.6%1.47%$8M-$3M0.81%$320MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Uniqure NVCurrentSHS49,800+233.7%$8M+$5M0.77%Q3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Surrozen, Inc./DENasdaq: SRZNCurrentBiological Products, (No Diagnostic Substances)COM NEWNew$8M+$8M0.76%Q3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Cue Biopharma, Inc.Nasdaq: CUECurrentPharmaceutical PreparationsCOM290,633+186,269+178.5%3.48%$8M+$4M0.76%$2MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
EUPRAXIA PHARMACEUTICALS INC.Nasdaq: EPRXCurrentPharmaceutical PreparationsCOM809,74100.0%$7M+$2M0.74%Q3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Erasca, Inc.Nasdaq: ERASCurrentPharmaceutical PreparationsCOMNew$7M+$7M0.74%$5.0BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Tectonic Therapeutic, Inc.Nasdaq: TECXCurrentBiological Products, (No Diagnostic Substances)COM306,338+100,501+48.8%1.54%$7M+$0.1M0.72%$411MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Monopar TherapeuticsNasdaq: MNPRCurrentPharmaceutical PreparationsCOM NEW86,761+38,900+81.3%1.28%$7M+$2M0.70%$476MQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
CRESCENT BIOPHARMA, INC.Nasdaq: CBIOCurrentPharmaceutical PreparationsCOM150,061+150,061New0.39%$7M+$7M0.66%$539MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Alpha Cognition Inc.Nasdaq: ACOGCurrentBiological Products, (No Diagnostic Substances)COM NEW701,259-135,000-16.1%3.18%$6M+$0.3M0.63%Q3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Immunome Inc.Nasdaq: IMNMCurrentPharmaceutical PreparationsCOM285,000+225,000+375.0%0.24%$6M+$5M0.62%$2.0BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Jade Biosciences, Inc.Nasdaq: JBIOCurrentPharmaceutical PreparationsCOM NEW427,34900.0%0.62%$6M-$3M0.60%$1.0BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Faeth Therapeutics, Inc.Nasdaq: FTHCurrentPharmaceutical PreparationsCOM NEW199,694+164,308+464.3%0.77%$6M+$5M0.60%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Freenome, Inc.Nasdaq: FRNMCurrentServices-Medical LaboratoriesCOMMON STOCK362,626+362,626New0.33%$6M+$6M0.57%Q3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Proqr Thrapeutics N VCurrentSHS EURO3,425,93000.0%$6M-$0.7M0.57%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Cardiol Therapeutics Inc.Nasdaq: CRDLCurrentBiological Products, (No Diagnostic Substances)COM CL A3,325,00000.0%$6M+$2M0.56%Q3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Olema Pharmaceuticals, Inc.Nasdaq: OLMACurrentPharmaceutical PreparationsCOM383,28100.0%0.44%$5M-$2M0.55%$626MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
RELMADA THERAPEUTICS, INC.Nasdaq: RLMDCurrentPharmaceutical PreparationsCOM1,448,359-700,000-32.6%1.36%$5M-$9M0.55%$332MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Pelthos Therapeutics Inc.NYSE: PTHSCurrentBiological Products, (No Diagnostic Substances)COM SHS256,59800.0%6.53%$5M-$2M0.54%Q3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Inventiva S.A.Nasdaq: IVACurrentPharmaceutical PreparationsADS1,129,10100.0%$5M+$1M0.54%$825MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Ovid Therapeutics Inc.Nasdaq: OVIDCurrentPharmaceutical PreparationsCOM2,119,704-150,000-6.6%1.12%$5M-$0.8M0.53%$442MQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
SPRUCE BIOSCIENCES, INC.Nasdaq: SPRBCurrentPharmaceutical PreparationsCOM NEW101,356-20,000-16.5%3.53%$5M-$2M0.50%$116MQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Dyne Therapeutics, Inc.Nasdaq: DYNCurrentPharmaceutical PreparationsCOMNew$5M+$5M0.49%$3.0BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Vor Biopharma Inc.Nasdaq: VORCurrentBiological Products, (No Diagnostic Substances)COM NEW250,000+250,000New0.41%$5M+$5M0.48%$1.1BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Vogenx, Inc.Nasdaq: VOGXCurrentPharmaceutical PreparationsCOM208,836+208,836New1.41%$5M+$5M0.48%$190MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Viridian Therapeutics, Inc.\DENasdaq: VRDNCurrentPharmaceutical PreparationsCOM225,000-200,000-47.1%0.20%$5M-$3M0.47%$3.6BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
BRIGHT MINDS BIOSCIENCES INC.Nasdaq: DRUGCurrentPharmaceutical PreparationsCOM NEW88,95100.0%$4M-$2M0.45%$204MQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
SELLAS Life Sciences Group, Inc.Nasdaq: SLSCurrentPharmaceutical PreparationsCOM NEW-16.6%$4M-$0.9M0.44%$3.0BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Zura Bio LtdNasdaq: ZURACurrentBiological Products, (No Diagnostic Substances)CLASS A ORD SHS1,018,492-200,000-16.4%1.06%$4M-$3M0.43%$92MQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Xencor IncNasdaq: XNCRCurrentPharmaceutical PreparationsCOMNew$4M+$4M0.43%$2.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
CUMBERLAND PHARMACEUTICALS INCNasdaq: CPIXCurrentPharmaceutical PreparationsCOM503,15300.0%3.36%$4M+$0.7M0.40%Q3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Rezolute, Inc.Nasdaq: RZLTCurrentPharmaceutical PreparationsCOM NEW935,01200.0%0.97%$4M-$1.0M0.39%$499MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Amanat Acquisition CorpCurrentCL A ORD349,836+199,836+133.2%$4M+$2M0.37%Q3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Bicara Therapeutics Inc.Nasdaq: BCAXCurrentPharmaceutical PreparationsCOMNew$4M+$4M0.37%$605MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Camp4 Therapeutics CorpNasdaq: CAMPCurrentPharmaceutical PreparationsCOM912,906+912,906New1.45%$4M+$4M0.37%$251MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Ocugen, Inc.Nasdaq: OCGNCurrentBiological Products, (No Diagnostic Substances)COM3,562,972-400,000-10.1%1.05%$4M-$2M0.37%$249MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Alector, Inc.Nasdaq: ALECCurrentBiological Products, (No Diagnostic Substances)COM1,982,60600.0%1.33%$4M-$0.3M0.37%$342MQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Avalo Therapeutics, Inc.Nasdaq: AVTXCurrentPharmaceutical PreparationsCOM NEW90,18300.0%0.16%$4M+$2M0.36%$390MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Silence Therapeutics plcNasdaq: SLNCurrentPharmaceutical PreparationsADS821,790-8,994-1.1%0.44%$3M+$1M0.33%$1.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Ginkgo Bioworks Holdings, Inc.NYSE: DNACurrentBiological Products, (No Diagnostic Substances)CL A NEW250,000+250,000New$3M+$3M0.32%$532MQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Atea Pharmaceuticals, Inc.Nasdaq: AVIRCurrentPharmaceutical PreparationsCOMNew$3M+$3M0.32%$316MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
IRulya Therapeutics Inc.Nasdaq: IRLACurrentBiological Products, (No Diagnostic Substances)COM95,652+23,401+32.4%0.88%$3M+$2M0.30%Q3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
ALUMIS INC.Nasdaq: ALMSCurrentPharmaceutical PreparationsCOM41,177-829,371-95.3%$3M-$32M0.30%$562MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Q32 Bio Inc.Nasdaq: QTTBCurrentPharmaceutical PreparationsCOM345,000-85,000-19.8%1.15%$3M-$5M0.29%$254MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
ARVINAS, INC.Nasdaq: ARVNCurrentPharmaceutical PreparationsCOM358,25700.0%0.55%$3M-$0.2M0.28%$441MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Connect Biopharma Hldgs LtdCurrentSHS2,235,534-2,303,000-50.7%$2M-$8M0.25%Q3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Rein Therapeutics, Inc.Nasdaq: RNTXCurrentPharmaceutical PreparationsCOM NEW2,950,00000.0%3.42%$2M-$0.7M0.24%$32MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
KAZIA THERAPEUTICS LTDNasdaq: KZIACurrentPharmaceutical PreparationsSPONSORED ADS246,201-150,000-37.9%<0.01%$2M-$3M0.24%Q3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Acumen Pharmaceuticals, Inc.Nasdaq: ABOSCurrentBiological Products, (No Diagnostic Substances)COM1,053,79700.0%1.46%$2M-$0.5M0.24%$14MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Invivyd, Inc.Nasdaq: IVVDCurrentBiological Products, (No Diagnostic Substances)COM2,656,57000.0%0.90%$2M-$0.0M0.23%$132MQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
ProMIS Neurosciences Inc.Nasdaq: PMNCurrentPharmaceutical PreparationsCOM SHS205,00000.0%2.28%$2M-$0.5M0.22%Q3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Obsidian Therapeutics, Inc.Nasdaq: OBXCurrentPharmaceutical PreparationsCOM158,942+158,942New0.26%$2M+$2M0.22%$751MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
CAPRICOR THERAPEUTICS, INC.Nasdaq: CAPRCurrentPharmaceutical PreparationsCOM NEW229,215-375,000-62.1%0.39%$2M-$21M0.22%$438MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
DELCATH SYSTEMS, INC.Nasdaq: DCTHCurrentSurgical & Medical Instruments & ApparatusCOM NEW135,667-50,000-26.9%0.39%$2M-$0.2M0.22%$669MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
4D Molecular Therapeutics, Inc.Nasdaq: FDMTCurrentBiological Products, (No Diagnostic Substances)COM150,037+150,037New$2M+$2M0.22%$604MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Neuronetics, Inc.Nasdaq: STIMCurrentSurgical & Medical Instruments & ApparatusCOM810,182+109,000+15.5%1.04%$2M+$1.0M0.19%$120MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Biohaven Ltd.NYSE: BHVNCurrentPharmaceutical PreparationsCOM133,181-615,000-82.2%0.09%$2M-$9M0.18%$2.1BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Lexeo Therapeutics, Inc.Nasdaq: LXEOCurrentBiological Products, (No Diagnostic Substances)COM513,01100.0%0.62%$2M-$0.7M0.17%$244MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Verastem, Inc.Nasdaq: VSTMCurrentPharmaceutical PreparationsCOM NEW213,86500.0%0.17%$2M+$0.9M0.17%$864MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Journey Medical CorpNasdaq: DERMCurrentPharmaceutical PreparationsCOM251,43600.0%$2M-$0.1M0.17%$100MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
IMMUNIC, INC.Nasdaq: IMUXCurrentPharmaceutical PreparationsCOM NEW182,464+115,000+170.5%1.15%$2M+$0.7M0.17%$117MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
PepGen Inc.Nasdaq: PEPGCurrentPharmaceutical PreparationsCOM693,539+246,374+55.1%1.00%$2M+$0.9M0.17%$370MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Fulcrum Therapeutics, Inc.Nasdaq: FULCCurrentPharmaceutical PreparationsCOM449,161-600,000-57.2%0.59%$2M-$2M0.17%$283MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Tyra Biosciences, Inc.Nasdaq: TYRACurrentPharmaceutical PreparationsCOM65,000+65,000New0.09%$1M+$1M0.14%$1.4BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
EyePoint, Inc.Nasdaq: EYPTCurrentLaboratory Analytical InstrumentsCOM NEW205,056-86.9%0.18%$1M-$9M0.14%$30MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Cabaletta Bio, Inc.Nasdaq: CABACurrentBiological Products, (No Diagnostic Substances)COM700,00000.0%0.32%$1M-$0.8M0.14%$218MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Tarsus PharmaceuticalsNasdaq: TARSCurrentBiological Products, (No Diagnostic Substances)COM16,858-14,308-45.9%0.03%$1M-$0.6M0.13%$3.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Sionna Therapeutics, Inc.Nasdaq: SIONCurrentPharmaceutical PreparationsCOM85,300-75.5%0.19%$1M-$4M0.12%$134MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
PALATIN TECHNOLOGIES INCNasdaq: PTNCurrentPharmaceutical PreparationsCOM NEW130,000+130,000New7.30%$1M+$1M0.12%$9MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
iBio, Inc.Nasdaq: IBIOCurrentPharmaceutical PreparationsCOM NEW957,06200.0%1.49%$1M-$0.5M0.11%$56MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Lipocine Inc.Nasdaq: LPCNCurrentPharmaceutical PreparationsCOM NEW508,55600.0%4.59%$1M-$0.2M0.11%$17MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Spdr S&p 500 Etf TRNYSE: SPYExitedFundTR UNIT0-25,000-100.0%-$193MQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
Terns Pharmaceuticals IncExitedCOM0-1,456,378-100.0%-$140MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Cidara Therapeutics, Inc.ExitedCOM NEW0-273,243-100.0%-$127MQ1 202615 May 2026Q4 2024Q4 202513F, Q4 2025
VERTEX PHARMACEUTICALS INC / MANasdaq: VRTXExitedPharmaceutical PreparationsCOM-100.0%-$93M$132BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
UNITED THERAPEUTICS CorpNasdaq: UTHRExitedPharmaceutical PreparationsCOM-100.0%-$89M$23.8BQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
CYTOKINETICS INCNasdaq: CYTKExitedPharmaceutical PreparationsCOM NEW0-283,572-100.0%-$82M$7.2BQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
AMGEN INCNasdaq: AMGNExitedBiological Products, (No Diagnostic Substances)COM0-45,000-100.0%-$80M$237BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Invesco QQQ TRExitedFundUNIT SER 1-100.0%-$58MQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
IONIS PHARMACEUTICALS INCNasdaq: IONSExitedPharmaceutical PreparationsCOM-100.0%-$56M$4.5BQ3 202616 Nov 2026Q3 2025Q2 202613F, Q2 2026
GENMAB A/SNasdaq: GMABExitedPharmaceutical PreparationsSPONSORED ADS0-175,000-100.0%-$53M$31.7BQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
Ishares TRExitedFundRUSSELL 2000 ETF-100.0%-$50MQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
TYSON FOODS, INC.NYSE: TSNExitedPoultry Slaughtering and ProcessingCL A-100.0%-$36M$22.0BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
RAPT TherapeuticsExitedCOM NEW0-665,271-100.0%-$32MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
OMEROS CORPNasdaq: OMERExitedPharmaceutical PreparationsCOM-100.0%-$26M$1.0BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Revolution Medicines, Inc.Nasdaq: RVMDExitedBiological Products, (No Diagnostic Substances)COM0-163,142-100.0%-$25M$34.5BQ2 202614 Aug 2026Q3 2025Q1 202613F, Q1 2026
Scholar Rock Holding CorpNasdaq: SRRKExitedBiological Products, (No Diagnostic Substances)COM-100.0%-$24M$6.1BQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
CORCEPT THERAPEUTICS INCNasdaq: CORTExitedPharmaceutical PreparationsCOM0-185,593-100.0%-$20M$7.1BQ1 202615 May 2026Q1 2025Q4 202513F, Q4 2025
ALNYLAM PHARMACEUTICALS, INC.Nasdaq: ALNYExitedPharmaceutical PreparationsCOM0-56,594-100.0%-$18M$19.8BQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Crinetics Pharmaceuticals IncExitedCOM-100.0%-$17MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
NEUROCRINE BIOSCIENCES INCNasdaq: NBIXExitedBiological Products, (No Diagnostic Substances)COM0-54,062-100.0%-$15M$15.8BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
NOVO NORDISK A SNYSE: NVOExitedPharmaceutical PreparationsADR-100.0%-$15M$171BQ2 202614 Aug 2026Q3 2025Q1 202613F, Q1 2026
Karyopharm Therapeutics IncKPTIQExitedCOM NEW0-733,435-100.0%-$14MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Verona Pharma PLCExitedSPONSORED ADS0-146,831-100.0%-$14MQ3 202514 Nov 2025Q4 2024Q2 202513F, Q2 2025
Apogee Therapeutics IncExitedCOM0-232,047-100.0%-$14MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
PILGRIMS PRIDE CORPNasdaq: PPCExitedPoultry Slaughtering and ProcessingCOM-100.0%-$14M$6.6BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Dianthus Therapeutics, Inc. /DE/Nasdaq: DNTHExitedPharmaceutical PreparationsCOM0-346,001-100.0%-$14MQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
CytomX Therapeutics, Inc.Nasdaq: CTMXExitedPharmaceutical PreparationsCOM0-3,172,616-100.0%-$14M$447MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Corbus Pharmaceuticals Holdings, Inc.Nasdaq: CRBPExitedPharmaceutical PreparationsCOM NEW0-284,715-100.0%-$13M$50MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Oruka Therapeutics, Inc.Nasdaq: ORKAExitedPharmaceutical PreparationsCOM0-242,021-100.0%-$12MQ2 202614 Aug 2026Q1 2025Q1 202613F, Q1 2026
Akero Therapeutics IncExitedCOM0-206,854-100.0%-$12MQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
Soleno Therapeutics IncExitedCOM0-344,123-100.0%-$12MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
ANAPTYSBIO, INCNasdaq: ANABExitedPharmaceutical PreparationsCOM0-48,410-100.0%-$11M$1.4BQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
ARROWHEAD PHARMACEUTICALS, INC.Nasdaq: ARWRExitedPharmaceutical PreparationsCOM0-38,278-100.0%-$11M$6.2BQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
MoonLake ImmunotherapeuticsNasdaq: MLTXExitedPharmaceutical PreparationsCLASS A ORD0-435,839-100.0%-$11M$939MQ4 202518 Feb 2026Q1 2025Q3 202513F, Q3 2025
Celcuity Inc.Nasdaq: CELCExitedServices-Medical LaboratoriesCOM0-105,545-100.0%-$11M$2.8BQ1 202615 May 2026Q1 2025Q4 202513F, Q4 2025
Blueprint Medicines CorpExitedCOM0-113,904-100.0%-$10MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Apellis Pharmaceuticals IncExitedCOM0-71,747-100.0%-$10MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Protagonist Therapeutics, IncNasdaq: PTGXExitedPharmaceutical PreparationsCOM-100.0%-$10M$8.1BQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
DexcomNasdaq: DXCMExitedSurgical & Medical Instruments & ApparatusCOM-100.0%-$9M$29.9BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
PTC THERAPEUTICS, INC.Nasdaq: PTCTExitedPharmaceutical PreparationsCOM0-118,657-100.0%-$9M$4.9BQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
Metsera IncExitedCOM-100.0%-$9MQ4 202518 Feb 2026Q1 2025Q3 202513F, Q3 2025
TRUPANION, INC.Nasdaq: TRUPExitedHospital & Medical Service PlansCOM-100.0%-$9M$1.6BQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
Avidity Biosciences IncExitedCOM-100.0%-$9MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Damora Therapeutics, Inc.Nasdaq: DMRAExitedPharmaceutical PreparationsCOM NEW0-335,710-100.0%-$9M$1.5BQ3 202616 Nov 2026Q4 2025Q2 202613F, Q2 2026
Ventyx Biosciences IncExitedCOM0-958,704-100.0%-$9MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Axsome Therapeutics, Inc.Nasdaq: AXSMExitedPharmaceutical PreparationsCOM-100.0%-$8M$7.1BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
CG Oncology, Inc.Nasdaq: CGONExitedBiological Products, (No Diagnostic Substances)COM0-199,473-100.0%-$8M$7.3BQ1 202615 May 2026Q2 2025Q4 202513F, Q4 2025
PALVELLA THERAPEUTICS, INC.Nasdaq: PVLAExitedPharmaceutical PreparationsCOM0-64,626-100.0%-$8M$2.1BQ2 202614 Aug 2026Q3 2025Q1 202613F, Q1 2026
MBX Biosciences, Inc.Nasdaq: MBXExitedPharmaceutical PreparationsCOM0-48,071-100.0%-$8M$2.7BQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
CAL-MAINE FOODS INCNasdaq: CALMExitedAgricultural Prod-Livestock & Animal SpecialtiesCOM NEW-100.0%-$8M$3.3BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
ArcellxExitedCOMMON STOCK-100.0%-$7MQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
Mineralys Therapeutics, Inc.Nasdaq: MLYSExitedPharmaceutical PreparationsCOM0-200,000-100.0%-$7M$1.3BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Black Diamond Therapeutics, Inc.Nasdaq: BDTXExitedBiological Products, (No Diagnostic Substances)COM-100.0%-$7MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
AGIOS PHARMACEUTICALS, INC.Nasdaq: AGIOExitedPharmaceutical PreparationsCOM0-115,489-100.0%-$7M$1.7BQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
Immunovant, Inc.Nasdaq: IMVTExitedBiological Products, (No Diagnostic Substances)COM-100.0%-$7M$6.7BQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Spyre Therapeutics, Inc.Nasdaq: SYREExitedPharmaceutical PreparationsCOM NEW0-282,159-100.0%-$7M$9.3BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Hims & Hers Health, Inc.NYSE: HIMSExitedServices-Offices & Clinics of Doctors of MedicineCOM CL A0-188,381-100.0%-$7M$3.8BQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Edgewise Therapeutics, Inc.Nasdaq: EWTXExitedPharmaceutical PreparationsCOM0-280,000-100.0%-$6MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Eli LillyNYSE: LLYExitedPharmaceutical PreparationsCOM0-6,547-100.0%-$6M$1.20TQ2 202614 Aug 2026Q1 2025Q1 202613F, Q1 2026
Nurix Therapeutics, Inc.Nasdaq: NRIXExitedPharmaceutical PreparationsCOM0-260,000-100.0%-$6M$1.5BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
ARS Pharmaceuticals, Inc.Nasdaq: SPRYExitedPharmaceutical PreparationsCOM-100.0%-$6M$338MQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
BeOne Medicines Ltd.Nasdaq: ONCExitedPharmaceutical PreparationsSPONSORED ADR-100.0%-$6M$45.7BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Syndax Pharmaceuticals IncNasdaq: SNDXExitedPharmaceutical PreparationsCOM0-333,733-100.0%-$5M$822MQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
Madrigal PharmaceuticalsNasdaq: MDGLExitedPharmaceutical PreparationsCOM-100.0%-$5M$9.2BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
BioAge Labs, Inc.Nasdaq: BIOAExitedPharmaceutical PreparationsCOM0-200,000-100.0%-$5M$216MQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Structure Therapeutics Inc.Nasdaq: GPCRExitedPharmaceutical PreparationsSPONSORED ADS0-163,237-100.0%-$5M$1.2BQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
Liquidia CorpNasdaq: LQDAExitedPharmaceutical PreparationsCOM NEW-100.0%-$5M$5.1BQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
Arcturus Therapeutics Holdings Inc.Nasdaq: ARCTExitedPharmaceutical PreparationsCOM0-10,721-100.0%-$4M$219MQ4 202518 Feb 2026Q4 2024Q3 202513F, Q3 2025
LENZ Therapeutics, Inc.Nasdaq: LENZExitedBiological Products, (No Diagnostic Substances)COM0-149,502-100.0%-$4M$105MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
ARGENX SENasdaq: ARGXExitedBiological Products, (No Diagnostic Substances)SPONSORED ADR0-5,942-100.0%-$4M$59.2BQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
ADMA BIOLOGICS, INC.Nasdaq: ADMAExitedBiological Products, (No Diagnostic Substances)COM0-234,854-100.0%-$4M$3.0BQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
BridgeBio Pharma, Inc.Nasdaq: BBIOExitedPharmaceutical PreparationsCOM0-57,417-100.0%-$4M$15.2BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Legend Biotech CorpNasdaq: LEGNExitedPharmaceutical PreparationsSPONSORED ADS0-226,888-100.0%-$4M$3.1BQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Absci CorpNasdaq: ABSIExitedServices-Commercial Physical & Biological ResearchCOM0-353,772-100.0%-$4M$1.4BQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Teva Pharmaceutical Inds LtdExitedSPONSORED ADS-100.0%-$4MQ4 202518 Feb 2026Q4 2024Q3 202513F, Q3 2025
Climb Bio, Inc.Nasdaq: CLYMExitedPharmaceutical PreparationsCOM0-300,000-100.0%-$4M$545MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Altimmune, Inc.Nasdaq: ALTExitedPharmaceutical PreparationsCOM NEW-100.0%-$4M$274MQ4 202518 Feb 2026Q4 2024Q3 202513F, Q3 2025
Krystal Biotech, Inc.Nasdaq: KRYSExitedBiological Products, (No Diagnostic Substances)COM0-14,814-100.0%-$4M$9.4BQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
Trevi Therapeutics, Inc.Nasdaq: TRVIExitedPharmaceutical PreparationsCOM0-575,000-100.0%-$4M$2.0BQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Prime Medicine, Inc.Nasdaq: PRMEExitedBiological Products, (No Diagnostic Substances)COM0-150,000-100.0%-$4M$856MQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
TG THERAPEUTICS, INC.Nasdaq: TGTXExitedPharmaceutical PreparationsCOM0-117,903-100.0%-$4M$9.8BQ1 202615 May 2026Q4 2024Q4 202513F, Q4 2025
Zenas BioPharma, Inc.Nasdaq: ZBIOExitedPharmaceutical PreparationsCOM-100.0%-$3M$1.7BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Aquestive Therapeutics, Inc.Nasdaq: AQSTExitedPharmaceutical PreparationsCOM-100.0%-$3M$466MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Gossamer Bio IncExitedCOM-100.0%-$3MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
GALECTIN THERAPEUTICS INCNasdaq: GALTExitedPharmaceutical PreparationsCOM NEW0-100-100.0%-$3M$283MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Forte Biosciences Inc.ExitedCOM NEW0-118,972-100.0%-$3MQ2 202614 Aug 2026Q4 2024Q1 202613F, Q1 2026
NEKTAR THERAPEUTICSNasdaq: NKTRExitedPharmaceutical PreparationsCOM NEW-100.0%-$3M$1.1BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Upstream Bio, Inc.Nasdaq: UPBExitedPharmaceutical PreparationsCOM0-161,113-100.0%-$3M$110MQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
CervoMed Inc.Nasdaq: CRVOExitedPharmaceutical PreparationsCOM0-202,345-100.0%-$3M$20MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Keros Therapeutics, Inc.Nasdaq: KROSExitedPharmaceutical PreparationsCOM0-274,009-100.0%-$3M$224MQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
Eledon Pharmaceuticals, Inc.Nasdaq: ELDNExitedPharmaceutical PreparationsCOM0-1,000,221-100.0%-$3M$160MQ3 202514 Nov 2025Q4 2024Q2 202513F, Q2 2025
BIOGEN INC.Nasdaq: BIIBExitedBiological Products, (No Diagnostic Substances)COM0-21,516-100.0%-$3M$36.5BQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
Perceptive Cap Solutions CorExitedCL A ORD SHS0-240,951-100.0%-$3MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Sarepta Therapeutics, Inc.Nasdaq: SRPTExitedPharmaceutical PreparationsCOM-100.0%-$3M$1.5BQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
Vir Biotechnology, Inc.Nasdaq: VIRExitedBiological Products, (No Diagnostic Substances)COM0-293,258-100.0%-$3M$1.7BQ2 202614 Aug 2026Q4 2024Q1 202613F, Q1 2026
Aligos Therapeutics, Inc.Nasdaq: ALGSExitedBiological Products, (No Diagnostic Substances)COM NEW0-64,300-100.0%-$3MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
ABEONA THERAPEUTICS INC.Nasdaq: ABEOExitedPharmaceutical PreparationsCOM NEW0-533,581-100.0%-$3M$151MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
NextCure, Inc.Nasdaq: NXTCExitedPharmaceutical PreparationsCOM NEW0-238,303-100.0%-$3MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Sana Biotechnology, Inc.Nasdaq: SANAExitedBiological Products, (No Diagnostic Substances)COM0-365,000-100.0%-$2M$521MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Annexon, Inc.Nasdaq: ANNXExitedPharmaceutical PreparationsCOM0-430,244-100.0%-$2M$651MQ3 202616 Nov 2026Q4 2025Q2 202613F, Q2 2026
ZEVRA THERAPEUTICS, INC.Nasdaq: ZVRAExitedPharmaceutical PreparationsCOM NEW0-292,772-100.0%-$2M$540MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Relay Therapeutics, Inc.Nasdaq: RLAYExitedBiological Products, (No Diagnostic Substances)COM0-467,362-100.0%-$2M$3.5BQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
Xenon Pharmaceuticals Inc.Nasdaq: XENEExitedPharmaceutical PreparationsCOM0-62,052-100.0%-$2M$3.7BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
BridgeBio Oncology Therapeutics, Inc.Nasdaq: BBOTExitedPharmaceutical PreparationsCOM NEW0-270,231-100.0%-$2M$149MQ2 202614 Aug 2026Q3 2025Q1 202613F, Q1 2026
Nuvalent IncExitedCOM0-23,594-100.0%-$2MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
NOVAVAX INCNasdaq: NVAXExitedBiological Products, (No Diagnostic Substances)COM NEW-100.0%-$2M$1.3BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Jazz Pharmaceuticals plcNasdaq: JAZZExitedPharmaceutical PreparationsSHS USD0-12,460-100.0%-$2M$15.2BQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
Evolus, Inc.Nasdaq: EOLSExitedPharmaceutical PreparationsCOM0-193,265-100.0%-$2M$463MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Replimune Group, Inc.Nasdaq: REPLExitedBiological Products, (No Diagnostic Substances)COM-100.0%-$2M$1.8BQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
GERON CORPNasdaq: GERNExitedPharmaceutical PreparationsCOM0-1,600,000-100.0%-$2M$588MQ3 202514 Nov 2025Q1 2025Q2 202513F, Q2 2025
Acelyrin IncExitedCOM0-676,608-100.0%-$2MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Cardiff Oncology, Inc.Nasdaq: CRDFExitedBiological Products, (No Diagnostic Substances)COM0-450,000-100.0%-$2MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Protara Therapeutics, Inc.Nasdaq: TARAExitedBiological Products, (No Diagnostic Substances)COM STK0-350,489-100.0%-$2M$148MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Larimar Therapeutics, Inc.Nasdaq: LRMRExitedPharmaceutical PreparationsCOM-100.0%-$2M$337MQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
Reneo Pharmaceuticals IncExitedCOM0-1,025,668-100.0%-$2MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Biomea Fusion, Inc.Nasdaq: BMEAExitedPharmaceutical PreparationsCOM-100.0%-$2MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Achilles Therapeutics PLCExitedSPONSORED ADS0-1,441,141-100.0%-$2MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Verve Therapeutics IncExitedCOM0-358,393-100.0%-$2MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
ROCKET PHARMACEUTICALS, INC.Nasdaq: RCKTExitedPharmaceutical PreparationsCOM0-221,911-100.0%-$1M$236MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Wave Life Sciences, Inc.Nasdaq: WVEExitedPharmaceutical PreparationsSHS0-85,285-100.0%-$1M$536MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Travere Therapeutics, Inc.Nasdaq: TVTXExitedPharmaceutical PreparationsCOM-100.0%-$1M$4.6BQ1 202615 May 2026Q4 2024Q4 202513F, Q4 2025
Catalyst Pharmaceuticals IncExitedCOM0-57,388-100.0%-$1MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Janux Therapeutics, Inc.Nasdaq: JANXExitedPharmaceutical PreparationsCOM0-54,691-100.0%-$1M$630MQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
Zymeworks Inc.Nasdaq: ZYMEExitedPharmaceutical PreparationsCOM0-72,787-100.0%-$1M$1.9BQ4 202518 Feb 2026Q2 2025Q3 202513F, Q3 2025
Marinus Pharmaceuticals IncExitedCOM NEW0-706,154-100.0%-$1MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Corvus Pharmaceuticals, Inc.Nasdaq: CRVSExitedPharmaceutical PreparationsCOM-100.0%-$1M$844MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Elicio Therapeutics, Inc.Nasdaq: ELTXExitedPharmaceutical PreparationsCOM0-100,000-100.0%-$1MQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Nuvation Bio Inc.NYSE: NUVBExitedPharmaceutical PreparationsCOM CL A0-619,258-100.0%-$1M$1.3BQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Teladoc Health, Inc.NYSE: TDOCExitedServices-Offices & Clinics of Doctors of MedicineCOM0-150,000-100.0%-$1M$1.4BQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
Allakos IncExitedCOM0-971,950-100.0%-$1MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Roivant Sciences Ltd.Nasdaq: ROIVExitedPharmaceutical PreparationsSHS0-100,609-100.0%-$1M$28.2BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Definium Therapeutics, Inc.Nasdaq: DFTXExitedMedicinal Chemicals & Botanical ProductsCOM SHS0-58,803-100.0%-$1M$4.0BQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
Milestone Pharmaceuticals Inc.Nasdaq: MISTExitedPharmaceutical PreparationsCOM0-466,030-100.0%-$1M$50MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
OnKure Therapeutics, Inc.Nasdaq: OKURExitedPharmaceutical PreparationsCOM CL A0-253,754-100.0%-$1M$114MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Tourmaline Bio IncExitedCOM0-67,927-100.0%-$1MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Sagimet Biosciences Inc.Nasdaq: SGMTExitedPharmaceutical PreparationsCOM SER A0-387,565-100.0%-$1M$692MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Perspective Therapeutics, Inc.NYSE: CATXExitedPharmaceutical PreparationsCOM NEW-100.0%-$1M$95MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Third Harmonic Bio IncExitedCOM0-100,000-100.0%-$1MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Inflarx NVExitedCOM0-722,066-100.0%-$1.0MQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
SANGAMO THERAPEUTICS, INCOTC: SGMOQExitedBiological Products, (No Diagnostic Substances)COM0-1,294,652-100.0%-$0.9MQ4 202518 Feb 2026Q4 2024Q3 202513F, Q3 2025
Aclaris Therapeutics, Inc.Nasdaq: ACRSExitedPharmaceutical PreparationsCOM0-350,000-100.0%-$0.9M$555MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
First Tracks Biotherapeutics, Inc.Nasdaq: TRAXExitedPharmaceutical PreparationsORD SHS0-42,775-100.0%-$0.9MQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
VERU INC.Nasdaq: VERUExitedPharmaceutical PreparationsCOM0-1,425,239-100.0%-$0.8M$36MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Direxion Shares Etf TrustExitedFundDAI BIO BEA ETF0-105,822-100.0%-$0.8MQ3 202616 Nov 2026Q3 2025Q2 202613F, Q2 2026
Iteos Therapeutics IncExitedCOM0-78,574-100.0%-$0.8MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Kezar Life Sciences IncExitedCOM NEW0-102,211-100.0%-$0.8MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Tvardi Therapeutics, Inc.Nasdaq: TVRDExitedPharmaceutical PreparationsCOM-100.0%-$0.7MQ4 202518 Feb 2026Q3 2025Q3 202513F, Q3 2025
Mind Medicine Mindmed IncExitedCOM NEW0-62,691-100.0%-$0.7MQ4 202518 Feb 2026Q3 2024Q3 202513F, Q3 2025
89bio IncExitedCOM0-100,000-100.0%-$0.7MQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
Centessa Pharmaceuticals PLCExitedSPONSORED ADS0-18,113-100.0%-$0.7MQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
Kalvista Pharmaceuticals IncExitedCOM0-35,119-100.0%-$0.7MQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
INSMED IncNasdaq: INSMExitedPharmaceutical PreparationsCOM PAR $.010-4,214-100.0%-$0.7M$31.7BQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Monte Rosa Therapeutics, Inc.Nasdaq: GLUEExitedBiological Products, (No Diagnostic Substances)COM0-136,575-100.0%-$0.6M$761MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Prothena Corp PLCExitedSHS-100.0%-$0.6MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Inhibrx Biosciences, Inc.Nasdaq: INBXExitedBiological Products, (No Diagnostic Substances)COM0-42,122-100.0%-$0.6M$1.1BQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Pyxis Oncology, Inc.Nasdaq: PYXSExitedPharmaceutical PreparationsCOMMON STOCK0-613,253-100.0%-$0.6M$201MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Springworks Therapeutics IncExitedCOM0-12,519-100.0%-$0.6MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Yarrow Bioscience, Inc.Nasdaq: YARWExitedPharmaceutical PreparationsCOM0-290,000-100.0%-$0.5M$217MQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
Elevation Oncology IncExitedCOM0-690,089-100.0%-$0.4MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Biomx IncExitedCOM NEW0-892,976-100.0%-$0.4MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Vigil Neuroscience IncExitedCOM0-31,360-100.0%-$0.2MQ3 202514 Nov 2025Q4 2024Q2 202513F, Q2 2025
Anebulo Pharmaceuticals, Inc.OTC: ANEBExitedPharmaceutical PreparationsCOM0-157,720-100.0%-$0.2MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Lyra Therapeutics IncLYRAExitedCOM NEW0-21,161-100.0%-$0.2M$0.1MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Aethlon Med IncExitedCOM NEW0-153,659-100.0%-$0.2MQ3 202514 Nov 2025Q4 2024Q2 202513F, Q2 2025